贝伐单抗联合用药治疗肺癌的研究进展

Reasearch Progress on Bevacizumab Combination Therapy for Lung Cancer Patients

贝伐单抗是一种重组人源化血管内皮生长因子受体单克隆抗体,是第一个在美国批准上市的抑制肿瘤血管生成的药物,其联合应用其他化疗药物如自噬抑制剂、铂类药物、多靶点抗叶酸制剂、表皮生长因子受体酪氨酸酶抑制剂、重组人血管内皮抑制素治疗肺癌具有良好的疗效。在临床上主要表现为提高缓解率,延长无进展生存期和总生存期。贝伐单抗的副作用主要是高血压、蛋白尿、出血、肝损害、轻微的动静脉血栓、充血性心力衰竭、胃穿孔等,其不良反应的产生与其使用浓度有一定的关系。本文就联合使用贝伐单抗治疗肺癌的临床研究进展进行综述。

Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factor receptor. It was the first clinically available angiogenesis inhibitor in the United States. Its combinations with other chemo- therapy drugs such as autophagy inhibitors, platinum drugs, muhitargeted antifolate agents, epidermal growth factor receptor tyrosine kinase inhibitors and recombinant human endostatin have good curative effects in the treatment of lung cancer. In clinical, it improves the response rate, and prolongs progression free survival and overall survival. The side effects of bevacizumab mainly include hypertension, proteinuria, bleeding, liver damage, minor arteriovenous thrombosis, congestive heart failure and gastric perforation. Yet these adverse reactions relate to the concentration of drug administration. In this paper, we reviewed the clinical research progress on the combination of bevacizumab in the treatment of lung cancer.